Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

, multinational, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 875 women, age 18 to 49, with moderate to severe endometriosis-associated pain. Approximately 160 sites in the United States, Puerto Rico and Canada are conducting this study.

AbbVie is also currently conducting a Phase II study of elagolix for uterine fibroids to assess blood loss in women with heavy uterine bleeding due to such fibroids. AbbVie expects a Phase IIb study in uterine fibroids to commence in 2013.

VMAT2 UpdateThe Company is currently conducting two Phase IIb studies of its VMAT2 inhibitor NBI-98854.

The Kinect Study is a 120 subject, placebo-controlled, double-blind, parallel design, multiple dose, 12-week study assessing six-week dosing of NBI-98854 against placebo, followed by six weeks of open-label treatment with NBI-98854. The primary endpoint is the Abnormal Involuntary Movement Scale (AIMS) at the end of the first six weeks of dosing. The study will also incorporate a capsule formulation of NBI-98854. Top-line data from the placebo-controlled portion of this study is expected in the second quarter of 2013.

The Kinect 2 Study is a 90 subject, placebo-controlled, double-blind, parallel design, multiple dose, six-week study assessing NBI-98854 against placebo. The primary endpoint is the AIMS at the end of the six weeks of dosing. Top-line data from this placebo-controlled study is expected in the third quarter of 2013.

Additionally, the Company is conducting appropriate preclinical studies to support the advancement of NBI-98854 into clinical trials for individuals suffering from Tourette's syndrome.

The Company anticipates and end-of-phase-II meeting for NBI-98854 in tardive dyskinesia to be held with the FDA in the fourth quarter of 2013.

Conference Call and Webcast Today at 8:00 AM Eastern Time
Neurocrine will hold a live conference call and webcast today at 8:00 a
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 Axovant Sciences Ltd. (NYSE:  AXON), ... dementia, today announced upcoming presentations at three investor conferences: ... Baird 2015 Healthcare Conference in New York ... September 10 at 2:00 PM at the BioCentury NewsMakers Conference ... Broadway Hotel & Conference Center , Thursday, September 17 ...
(Date:9/2/2015)... ... 02, 2015 , ... The wet form of macular degeneration, ... endothelial growth factor agents given by injection into the eye. Dry macular degeneration ... protocol for the many millions diagnosed with it. AMD usually starts in older ...
(Date:9/2/2015)... ... September 02, 2015 , ... Drug companies increasingly are ... BCC Research reveals in its new report that the U.S. will generate the ... and generates the most market demand. , BCC Research examines plant-derived drugs ...
(Date:9/2/2015)... TEL-AVIV, Israel , September 2, 2015 /PRNewswire/ ... BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, announced today ... treatment of glaucoma will be delivered at the ... of the European Society of Cataract & Refractive ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... Reports Results for the Nine Month Period Ended September ... ... Genmab A/S,(OMX: GEN) announced today results for the nine-month period ended,September 30, ... DKK 667 million (USD 128 million) for the nine,month period ended September ...
... BOSTON, Oct. 29 PAREXEL International,Corporation (Nasdaq: ... services,provider, in partnership with Glenmark Pharmaceuticals Ltd, ... the Good Clinical Practice Journal (GCPj) as,the ... Strategy Award. The,award recognizes the impressive collaborative ...
... announced today the,successful completion of a EUR ... in the development and commercialization of Furanics, ... improvement of,pharmaceutical products. The financing will be ... The focus of the next-generation biofuel,and bioplastic ...
Cached Biology Technology:Genmab Announces Results for the First Nine Months of 2008 2Genmab Announces Results for the First Nine Months of 2008 3Genmab Announces Results for the First Nine Months of 2008 4Genmab Announces Results for the First Nine Months of 2008 5PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy 2PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy 3PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy 4PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy 5Avantium Completes EUR 18 Million Financing Round 2Avantium Completes EUR 18 Million Financing Round 3Avantium Completes EUR 18 Million Financing Round 4
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
(Date:8/11/2015)... Sweden , August 11, 2015 Today, ... FPC1155. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015  Today, ... will visit Crossmatch ™ to learn firsthand ... and protect data. Crossmatch is a world leader ... technologies and expertise are helping federal agencies and ... and security.   "The vast majority ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... , This release is available in French . ... affects over 12 million people worldwide, with more than 2 million ... how the parasite survives inside human cells. That mystery has now ... Signaling by a team led by Dr. Martin Olivier ...
... of liquorice during pregnancy could adversely affect their child,s ... study of eight year old children whose mothers ate ... not perform as well as other youngsters in cognitive ... poor attention spans and show disruptive behaviour such as ...
... Vaccination can lower children,s risk of allergy. Cathleen ... for allergy prevention in the current issue of ... 625-31). Allergic diseases are becoming increasingly common in ... based treatment of allergic asthma, hay fever, or atopic ...
Cached Biology News:Major discovery opens door to leishmania treatment 2Eating liquorice in pregnancy may affect a child's IQ and behavior 2
... Mouse monoclonal [3D12] to Lambda ... Mixture of light chains of ... Specific for independent constantly expressed epitope ... and dimer forms of free lambda ...
Cells are grown to a specified density and induced, when necessary. Protein expression samples are collected at 3 growth points and analyzed by SDS-PAGE/Coomassie....
... provides cost effective cell culture services for ... antibodies. Quality at a reasonable price is ... research or commercial product, we strive toward ... as roller bottles, hollow fiber, and bioreactor ...
... optimized for maximum packaging efficiencies of T7Select ... extracts (> 109 pfu/g with control DNA) ... containing at least 5 107 recombinant ... made from a specially designed phage that ...
Biology Products: